AAV-Cas13 Antiviral Delivery for EV71 RNA Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a pressing need for effective vaccines and therapeutics to prevent or treat Enterovirus 71 (EV71) infections, which are highly contagious and can lead to severe neurological diseases with no commercially available options, and current clinical trials are limited to vaccine modalities.
Innovation Solution
Administering a recombinant adeno-associated virus (AAV) containing a Cas13 nuclease and guide RNAs to inhibit RNA viral nucleic acids, specifically targeting Enterovirus 71, by delivering the AAV at a dose of 5×10^11 to 5×10^13 vector genomes per kilogram of subject weight.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a recombinant AAV containing Cas13 nuclease and guide RNAs is administered to inhibit RNA viral nucleic acids, then the effectiveness of treating EV71 infection is improved, but the complexity of the therapeutic system increases
Solution Approach 1:
The patent embeds the CRISPR-Cas13 therapeutic system within a recombinant AAV vector. The AAV capsid encapsulates the nucleic acid sequences encoding Cas13 nuclease and guide RNAs, creating a nested structure where the delivery vehicle (AAV) contains the therapeutic payload (CRISPR system). This nesting approach consolidates multiple functional components into a single administered unit, improving therapeutic effectiveness while managing system complexity through integrated design.
Solution Approach 2:
The recombinant AAV serves as an intermediary delivery mechanism between the therapeutic CRISPR-Cas13 system and the target EV71 virus. The AAV vector mediates the transport of nucleic acid sequences encoding the nuclease and guide RNAs into infected cells, enabling the CRISPR system to function without direct administration of the complex enzymatic components. This intermediary approach simplifies the therapeutic delivery process while maintaining high effectiveness.
2Reliability
If a recombinant AAV is administered at a dose of 5×10^11 to 5×10^13 vgs/kg to inhibit viral nucleic acids, then the prevention and treatment of EV71 infection is improved, but the manufacturing precision requirements increase
Solution Approach 1:
The patent establishes a specific dosage range (5×10^11 to 5×10^13 vector genomes per kilogram) to optimize the balance between therapeutic effectiveness and manufacturing feasibility. By defining this parameter range, the invention allows for flexible production scaling while maintaining consistent clinical outcomes. The dosage parameter serves as a critical control point that translates laboratory efficacy into reliable clinical application, reducing the stringency of manufacturing precision requirements compared to fixed-dose approaches.
3Reliability
If the AAV targets RNA viral nucleic acids in skeletal and central nervous system cells, then the reduction of disease progression and pathology is improved, but the difficulty of delivering the therapy to these specific tissues increases
Solution Approach 1:
The patent employs AAV serotypes with tissue-specific tropism to achieve localized delivery of the CRISPR-Cas13 system to skeletal muscle and central nervous system cells. Different AAV serotypes (e.g., AAV2 for muscle, AAV9 for CNS) are selected based on the target tissue, enabling the therapy to concentrate its effect where needed while minimizing off-target effects. This local quality approach improves therapeutic reliability by ensuring the nuclease and guide RNAs are delivered precisely to infected cells in the skeletal and CNS compartments.
Solution Approach 2:
The recombinant AAV vector serves multiple functions simultaneously: it acts as a delivery vehicle, provides tissue-specific targeting through serotype selection, and enables the expression of both Cas13 nuclease and guide RNAs within the target cell. This multi-functionality consolidates what would otherwise require separate therapeutic components into a single administered agent, greatly simplifying the delivery process to skeletal and CNS tissues while maintaining high therapeutic reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively prevents and treats EV71 infections by inhibiting viral nucleic acids in skeletal and central nervous system cells, reducing disease progression and pathology in mouse models, and demonstrating potential for broad-spectrum antiviral activity against multiple Enterovirus strains.
Implementation Method 1
The AAV comprises at least one heterologous nucleic acid sequence encoding a Cas13 nuclease... effectively prevents and treats EV71 infections by inhibiting viral nucleic acids
Implementation Method 2
The AAV comprises at least one heterologous nucleic acid sequence encoding a Cas13 nuclease and one or more guide RNAs... specifically targeting Enterovirus 71
Implementation Method 3
Administering a recombinant adeno-associated virus (AAV) containing a Cas13 nuclease and guide RNAs... at a dose of 5×10^11 to 5×10^13 vector genomes per kilogram of subject weight
Data Source
AI summary
The present invention relates generally to the field of molecular biology. In particular, the specification teaches methods of preventing or treating an RNA viral infection in a subject.